Skip to main content

Table 1 Demographics and baseline characteristics of patients

From: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

 

All patients

Patients not admitted to hospital

Hospitalized, discharged alive

Hospitalized, deceased

n = 58

n = 22

n = 22

n = 14

Demographics

 Age (years)

67

[12.5]

64

[11.5]

71

[18.5]

68

[8]

 Sex (male)

52%

(30)

32%

(7)

68%

(15)

57%

(8)

 Race (non-White)

63%

(36/57)

55%

(12)

55%

12

92%

(12)

 BMI (kg/m2)

27.6

[7.9]

26.1

[5.3]

28.2

[10.2]

29.5

[9.9]

 Obesity (BMI > 30 kg/m2)

37%

(21/57)

27%

(6)

38%

(8/21)

50%

(7)

Comorbidities

 High cardiovascular risk profile (≥ 2 of hypertension, hyperlipidemia, diabetes)

55%

(32)

36%

(8)

64%

(14)

71%

(10)

  Hypertension

64%

(37)

59%

(13)

59%

(13)

79%

(11)

  Hyperlipidemia

62%

(36)

50%

(11)

59%

(13)

86%

(12)

  Diabetes

28%

(16)

9%

(2)

45%

(10)

29%

(4)

 Previous atherosclerotic complications (CAD and/or CVA)

22%

(13)

0%

(0)

36%

(8)

36%

(5)

  Congestive heart failure

12%

(7)

0%

(0)

14%

(3)

29%

(4)

  Current or former smoker

37%

(21/57)

27%

(6)

38%

(8/21)

50%

(7)

 Lung disease (COPD, emphysema, asthma, bronchiectasis)

21%

(12)

18%

(4)

27%

(6)

14%

(2)

 Chronic kidney disease (eGFR < 60 mL/min)

24%

(14)

23%

(5)

27%

(6)

21%

(3)

  History of other malignancy

9%

(5)

5%

(1)

5%

(1)

21%

(3)

  Number of comorbidities

2

[3]

1

[1.75]

3

[3]

3.5

[1.75]

Concomitant medication

 Anticoagulation

21%

(12)

9%

(2)

27%

(6)

29%

(4)

 Aspirin

59%

(34)

59%

(13)

59%

(13)

57%

(8)

 Statin

47%

(27)

14%

(3)

59%

(13)

79%

(11)

 ACE inhibitor or angiotensin II receptor blocker

45%

(26)

36%

(8)

41%

(9)

64%

(9)

 Beta blocker

34%

(20)

9%

(2)

50%

(11)

50%

(7)

 Metformin

16%

(9)

5%

(1)

32%

(7)

7%

(1)

 Non-steroidal anti-inflammatory drug

5%

(3)

5%

(1)

5%

(1)

7%

(1)

 Oral corticosteroids

53%

(31)

45%

(10)

50%

(11)

71%

(10)

 COVID-19 confirmed by PCR at MSH

71%

(41)

59%

(13)

86%

(19)

64%

(9)

  1. Note: values are presented as percentage (n) or median [interquartile range]
  2. Abbreviations: BMI body mass index, CAD coronary artery disease, CVA cerebrovascular accident, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, ACE angiotensin-converting enzyme, NSAID non-steroidal anti-inflammatory drug, MSH Mount Sinai Hospital